CompletedNot Applicable

Study of Progression to Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Incidence/Management and Treatment

United States34,960 participantsStarted 2023-04-20

Plain-language summary

The primary objective for this trial is to investigate the incidence probability of progression to Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) in patients with fibrosing ILD other than Idiopathic Pulmonary Fibrosis (IPF) in real-world setting in Japan. The secondary objective is to investigate the characteristics of procedures for management and treatment in patients with fibrosing ILD other than IPF in real-world setting in Japan.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients diagnosed with at least two fibrosing Interstitial Lung Disease (ILD) codes on different dates in the patient identification period
✓. Patients aged 18 years and older on the index date
✓. Patients for whom data for the 12 months prior to the index date can be extracted as baseline data

Exclusion criteria

✕. Patients grouped into the underlying disease of Idiopathic Pulmonary Fibrosis (IPF)
✕. Patients who have met PF-ILD progression criteria during the baseline period

What they're measuring

Incidence Probability of Progression to Pulmonary Fibrosing-Interstitial Lung Disease (PF-ILDs)

Timeframe: At 6, 12, 18 and 24 months after the index date, defined between 01-Jan-2013 and 6 months before 28-May-2020

Trial details

NCT IDNCT05875532

SponsorBoehringer Ingelheim

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2023-05-01

Results submitted2024-04-25

View on ClinicalTrials.gov More Lung Diseases, Interstitial trials